Agency Forms Undergoing Paperwork Reduction Act Review
Published Date: 6/26/2026
Notice
Summary
The CDC is asking for public feedback on a new form they want to use for health surveys. They’re making sure the form is useful, clear, and easy to fill out, and they want to keep the time and cost low for everyone involved. You’ve got 30 days to share your thoughts before the government gives the final thumbs-up!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12790 — Order Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Exists
The CDC is keeping a temporary ban on letting certain people enter the U.S. from countries where serious contagious diseases are spreading. This pause started June 21, 2026, and will last until July 21, 2026, unless changed sooner. It affects travelers from those countries and helps protect public health without any new fees or costs.
2026-12281 — Proposed Data Collection Submitted for Public Comment and Recommendations
The CDC wants your thoughts on a plan to keep checking workplace health hazards like chemicals and noise. This affects workers, employers, and safety pros who rely on these checks to stay safe. Comments are open until August 17, 2026, and the goal is to keep the process smooth without adding extra paperwork or costs.
2026-12275 — Proposed Data Collection Submitted for Public Comment and Recommendations
The CDC wants your thoughts on a plan to collect data that helps stop bad childhood experiences before they happen. This affects groups working to protect kids by improving how they track and prevent these issues. Comments are open until August 17, 2026, and this effort aims to make prevention smarter without adding extra hassle or costs.
2026-11821 — Agency Forms Undergoing Paperwork Reduction Act Review
The CDC is asking for public feedback on a new form about healthcare workers’ exposure to waste anesthetic gases. They want to make sure the form is useful, clear, and not too much work to fill out. You’ve got 30 days to share your thoughts, so don’t miss your chance to help shape this important health survey!
2026-11555 — Agency Forms Undergoing Paperwork Reduction Act Review
The CDC is asking for your thoughts on a new survey project to improve health data collection. They want to make sure the forms are useful, clear, and not too much work for people to fill out. You’ve got 30 days to share your ideas, so don’t miss your chance to help shape this important health survey!
2026-11557 — Proposed Data Collection Submitted for Public Comment and Recommendations
The CDC wants your thoughts on a new plan to collect info about people exposed to Andes Hantavirus during cruises and travel. This helps track and study cases to keep everyone safer. If you have ideas, send them by August 10, 2026—no extra costs for the public, just smarter health tracking!
Previous / Next Documents
Previous: 2026-12957 — Sunshine Act Meetings; Correction
The Postal Service fixed some missing details about their Board of Governors meeting on May 8, 2026. They clarified the exact times, location, and what topics will be covered during the closed morning session and the open afternoon session. This update helps everyone stay in the loop with no extra costs or delays.
Next: 2026-12959 — Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that the 5 mg prednisolone tablet wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can keep getting approval to sell their versions of this medicine, as long as they follow the rules. Patients and pharmacies can expect continued access to affordable generics without any interruptions or extra costs.